Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Alzheimer's Disease

    San Antonio, TX

    Search
    Alzheimer's Disease
    San Antonio, TX
    Show Map
    Map View
    San Antonio, TX
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      84 Alzheimer's Disease Trials near San Antonio, TX

      Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      KarXT + KarX-EC for Alzheimer's Disease

      San Antonio, Texas
      The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Pulmonary, Renal, Others

      600 Participants Needed

      KarXT for Psychosis in Alzheimer's Disease

      San Antonio, Texas
      The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others

      406 Participants Needed

      Donanemab for Alzheimer's Disease

      San Antonio, Texas
      This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:65 - 80

      Key Eligibility Criteria

      Disqualifiers:Mild Cognitive Impairment, Dementia, Cancer, Others
      Must Not Be Taking:Cognitive Enhancers

      2996 Participants Needed

      Semaglutide for Early Alzheimer's Disease

      San Antonio, Texas
      This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others
      Must Be Taking:Alzheimer's Treatments

      1840 Participants Needed

      Donanemab for Early Alzheimer's Disease

      San Antonio, Texas
      This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:MRI/PET Contraindication, Others
      Must Not Be Taking:Immunoglobulin G Therapy

      1736 Participants Needed

      KarXT + KarX-EC for Agitation in Alzheimer's Disease

      San Antonio, Texas
      The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Urinary Retention, Others
      Must Not Be Taking:MAO Inhibitors, Anticonvulsants, Mood Stabilizers, Tricyclics

      352 Participants Needed

      JNJ-64042056 for Alzheimer's Disease

      San Antonio, Texas
      The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 75

      Key Eligibility Criteria

      Disqualifiers:Alzheimer's Dementia, Mild Cognitive Impairment, Others

      498 Participants Needed

      CT1812 for Early Alzheimer's Disease

      San Antonio, Texas
      This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Other Dementias, Neurodegenerative Conditions, Hepatitis, Others

      540 Participants Needed

      Mevidalen for Alzheimer's Disease

      San Antonio, Texas
      The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Childbearing Potential, CNS Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors, Inducers

      300 Participants Needed

      Transcranial Direct Current Stimulation for Alzheimer's Disease

      San Antonio, Texas
      Participants will be asked to participate in this research study of a device that creates transcranial direct current stimulation (tDCS). The researchers hope to learn if 30 minute sessions of transcranial direct current stimulation (tDCS) improve such a mood or feelings in people with Alzheimer's Disease. This study involves the use of an investigational device called a tDC stimulator. "Investigational" means that the device has not yet been approved by the U.S. Food \& Drug Administration (FDA) for treating Alzheimer's Disease. This study will help find out what effects, good and/or bad, this has. The safety of this device in humans has been tested in prior research studies; however, some side effects may not yet be known.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Unstable Conditions, Epilepsy, Dementia, Suicidal Risk, Others

      24 Participants Needed

      Donepezil for Dementia

      San Antonio, Texas
      The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are: * Can an intervention's outcome be better assessed by a latent variable ("δ") integrating cognitive performance with functional status? * Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity? * Can a latent variable, derived from information collected remotely from caregivers, preselect subjects most likely to respond to the intervention? * Is the effect of the intervention in fact medicated by changes in the targeted biomarker? In this case, the biomarker will be a latent variable derived from several proteins measured in blood (i.e., so-called "adipokines"). The intervention will be donepezil, a medication approved for the treatment of Alzheimer's Disease, but only recently associated with adipokine changes. Participants with cognitive impairment and their caregivers will be interviewed by telephone and those newly prescribed donepezil by their provider for cognitive impairment will be recruited and enrolled. On the basis of the caregiver's report, the cognitively impaired subjects will be assigned to two groups based on a prediction of their response to donepezil. Researchers will compare those groups to see if dementia severity, as measured by δ, improves in predicted responders, and whether the change in the d-score is mediated by changes in adipokines.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:65 - 100

      Key Eligibility Criteria

      Disqualifiers:Psychosis, Parkinson's, Cancer, Others
      Must Be Taking:Donepezil

      200 Participants Needed

      Sensory Stimulation for Alzheimer's Disease

      San Antonio, Texas
      This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll in the OLE Hope Study (CA-0015). All participants will be treated with an Active Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months. There will be no Sham treatment group or randomization involved in this study.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:50 - 92

      Key Eligibility Criteria

      Disqualifiers:Insufficient Adherence, Continuous Care, Others
      Must Not Be Taking:Immunomodulators, Memantine, Nootropics

      402 Participants Needed

      ATI-045 for Eczema

      San Antonio, Texas
      This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Anaphylaxis, Corticosteroid Allergy, Others
      Must Not Be Taking:Antibiotics, Corticosteroids, Biologics, Others

      96 Participants Needed

      Semaglutide for Early Alzheimer's Disease

      San Antonio, Texas
      This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others
      Must Be Taking:Alzheimer's Treatments

      1840 Participants Needed

      AVP-786 for Agitation in Alzheimer's Disease

      San Antonio, Texas
      This trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1197 Participants Needed

      Remternetug for Alzheimer's Disease

      Shavano Park, Texas
      This trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:Unstable Illnesses, Cancer, Psychiatric Diagnosis, Others
      Must Not Be Taking:Anti-amyloid Immunotherapy

      1667 Participants Needed

      ABBV-916 for Early Alzheimer's Disease

      San Antonio, Texas
      This trial is testing a new drug called ABBV-916 to see if it can help people aged 50-90 who are in the early stages of Alzheimer's disease. Participants will receive the drug regularly over several months. The study aims to find out if the drug is safe and effective by monitoring changes in symptoms and side effects.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Vasogenic Edema, Microhemorrhages, Others
      Must Not Be Taking:Anticoagulants

      106 Participants Needed

      Sensory Stimulation for Alzheimer's Disease

      San Antonio, Texas
      This trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Seizure Disorder, Schizophrenia, Heart Disease, Others
      Must Be Taking:Acetylcholinesterase Inhibitors

      600 Participants Needed

      ALIA-1758 Safety Study in Healthy Participants

      San Antonio, Texas
      This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 40

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      52 Participants Needed

      Rapamycin for Alzheimer's Disease

      San Antonio, Texas
      This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 89

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Liver Disease, Heart Failure, Others
      Must Be Taking:AD Medications

      40 Participants Needed

      Why Other Patients Applied

      "I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

      WU
      Healthy Volunteer PatientAge: 76

      "I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

      OF
      Alzheimer's Disease PatientAge: 65

      "I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

      EK
      Mild Cognitive Impairment PatientAge: 72

      "I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

      AH
      Dementia PatientAge: 64

      "I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

      VL
      Alzheimer's PatientAge: 71
      Match to a Alzheimer's Disease Trial

      ACI-24.060 for Alzheimer's Disease and Down Syndrome

      San Antonio, Texas
      The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:35 - 85

      Key Eligibility Criteria

      Disqualifiers:Unstable Medical Condition, Drug Abuse, Seizures, Others
      Must Be Taking:Acetylcholinesterase Inhibitors, Memantine

      140 Participants Needed

      BIIB080 for Alzheimer's Disease

      San Antonio, Texas
      In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. * Clinicians use the CDR-SB to measure several categories of dementia symptoms. * The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of BIIB080. The study will be split into 2 parts. The 1st part is the Placebo-Controlled Period. The 2nd part is the Long-Term Extension (LTE) Period. The 2nd part of the study will help researchers learn about the long-term safety of BIIB080, and how it affects the participant's daily life, thinking, and memory abilities in the longer term. A description of how the study will be done is given below. * After screening, participants will first receive either a low dose or high dose of BIIB080, or a placebo, as an injection into the fluid around the spinal cord (cerebrospinal fluid). A placebo looks like the study drug but contains no real medicine. * Participants will receive BIIB080 or placebo once every 12 weeks or 24 weeks. * After 76 weeks of treatment in the Placebo-Controlled Period, eligible participants will move onto the Extension Treatment period, which will last 96 weeks. * In the extension period, participants who received placebo will be switched to high dose BIIB080 every 12 or 24 weeks. * Participants may be in the study for up to 201 weeks, or about 4 years. This includes the screening and follow-up periods. * Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period. * After the screening period, most participants will visit the clinic every 6 weeks.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Allergy To BIIB080, Unstable AD Meds, MRI Contraindications, Others
      Must Not Be Taking:Anti-amyloid Antibodies

      416 Participants Needed

      Nicotine Patch for Mild Cognitive Impairment

      San Antonio, Texas
      The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Tobacco Use, Neurologic Disease, Major Depression, Others
      Must Be Taking:Memantine, Cholinesterase Inhibitors

      380 Participants Needed

      Escitalopram for Agitation in Alzheimer's Disease

      San Antonio, Texas
      The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      187 Participants Needed

      LOCK Sleep Program for Dementia

      San Marcos, Texas
      This study seeks to improve clinical outcomes for an important, growing, and vulnerable population-nursing home residents with Alzheimer's disease or related dementias-by testing an evidence-based intervention to improve these residents' sleep. It will also examine the implementation and sustainment of this intervention.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Untreated OSA, Parkinson's, Others

      456 Participants Needed

      [18F]PI-2620 PET Imaging for Alzheimer's Disease

      Kerrville, Texas
      This trial tests a brain scan that uses a special substance to detect harmful proteins in people with Alzheimer's disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Aggressive Treatment, Brain Lesions, Others
      Must Not Be Taking:Amyloid, Tau Therapies

      200 Participants Needed

      Buntanetap for Alzheimer's Disease

      Austin, Texas
      The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      760 Participants Needed

      Xanamem for Alzheimer's Disease

      Austin, Texas
      Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Non-AD Dementia, Major Mental Illness, Diabetes, Others
      Must Be Taking:Symptomatic AD Medications

      220 Participants Needed

      BMS-986368 for Alzheimer's Disease

      Austin, Texas
      This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Schizoaffective, Others

      120 Participants Needed

      Long-Term Safety of Simufilam for Alzheimer's Disease

      Austin, Texas
      The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:51 - 89

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1081 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Alzheimer's Disease clinical trials in San Antonio, TX pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Alzheimer's Disease clinical trials in San Antonio, TX work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Alzheimer's Disease trials in San Antonio, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in San Antonio, TX for Alzheimer's Disease is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in San Antonio, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Alzheimer's Disease medical study in San Antonio, TX?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Alzheimer's Disease clinical trials in San Antonio, TX?

      Most recently, we added KarXT + KarX-EC for Alzheimer's Disease, Trontinemab for Alzheimer's Disease and P-tau217 Test for Alzheimer's Disease to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Texas

      Anxiety Clinical Trials in Texas

      Schizophrenia Clinical Trials in Texas

      ADHD Clinical Trials in Texas

      Bipolar Disorder Clinical Trials in Texas

      Multiple Sclerosis Clinical Trials in Texas

      Autism Clinical Trials in Texas

      Treatment Resistant Depression Clinical Trials in Texas

      Borderline Personality Disorder Clinical Trials in Texas

      Social Anxiety Disorder Clinical Trials in Texas

      Parkinson's Disease Clinical Trials in Texas

      Alzheimer's Disease Clinical Trials in Texas

      By Location

      Clinical Trials near Houston, TX

      Clinical Trials near Dallas, TX

      Clinical Trials near San Antonio, TX

      Clinical Trials near Austin, TX

      Clinical Trials near Fort Worth, TX

      Clinical Trials near Plano, TX

      Clinical Trials near Tyler, TX

      Clinical Trials near El Paso, TX

      Clinical Trials near Lubbock, TX

      Clinical Trials near Galveston, TX

      Clinical Trials near Temple, TX

      Clinical Trials near Arlington, TX

      Other People Viewed

      By Subject

      43 Alzheimer's Disease Trials near Austin, TX

      78 Alzheimer's Disease Trials near San Diego, CA

      32 Alzheimer's Disease Trials near Syracuse, NY

      45 Alzheimer's Disease Trials near San Francisco, CA

      72 Alzheimer's Disease Trials near Albuquerque, NM

      59 Alzheimer's Disease Trials near Phoenix, AZ

      42 Alzheimer's Disease Trials near Raleigh, NC

      27 Alzheimer's Disease Trials near Cincinnati, OH

      79 Osteoporosis Trials near San Diego, CA

      Top Clinical Trials near San Antonio, TX

      Top Clinical Trials near San Antonio, TX

      Top Depression Clinical Trials near San Antonio, TX

      By Trial

      Xanomeline + Trospium for Agitation in Alzheimer's Disease

      High-Fat Diet for Alzheimer's Disease

      Trazodone for Early Alzheimer's Disease

      Glycine + N-acetylcysteine for Alzheimer's Disease

      Rivastigmine for Delirium

      Omeprazole + Lifestyle Therapy for Laryngopharyngeal Reflux

      Brain Stimulation for Parkinson's Disease

      Cognitive Behavioral Intervention for Caregiver Stress Syndrome

      Virtual Reality for Upper Limb Rehabilitation After Stroke

      Migalastat for Fabry Disease

      PF-06651600 for Alopecia Areata

      PAINAD Scale for Painful Dementia

      Related Searches

      Top Alzheimers-disease Clinical Trials near Glendale, AZ

      Top Alzheimers-disease Clinical Trials near Chicago, IL

      Top Alzheimers-disease Clinical Trials near Los Angeles, CA

      Top Alzheimers-disease Clinical Trials near Las Vegas, NV

      Top Alzheimers-disease Clinical Trials near Columbia, SC

      Top Alzheimers-disease Clinical Trials near Houston, TX

      Top Alzheimers-disease Clinical Trials near Cincinnati, OH

      Bone Health Referral for Joint Replacement Surgery

      NeuroEPO for Alzheimer's Disease

      Selumetinib + Cyclosporine for Colorectal Cancer

      Data Accountability + Doula Support for Maternal Health Disparities

      Buntanetap for Alzheimer's Disease